Treatment for SI joint dysfunction generally includes non-surgical options such as rest, physical therapy, manual manipulation, and injections, with surgery as a last resort. Proper posture ...

Nevro recently announced its Nevro1 SI Joint Fusion System has been shown to outperform traditional surgical approaches in ...

Vyrsa is expected to be accretive to Nevro in 2024 for both revenue and AEBITDA. The latest acquisition is expected to strengthen Nevro’s foothold in the SI joint treatment space. Rationale ...

NVRO recently announced the publication of new data in the journal, Medical Devices: Evidence and Research, demonstrating the ...